Remove BMI Remove Cardiomyopathy Remove Preserved Ejection Fraction
article thumbnail

Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

European Journal of Heart Failure

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%

article thumbnail

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Circulation

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks.